Immunotherapy

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors, despite the natural weakening of the immune system that occurs with age. This promising conclusion comes from a new study conducted by researchers at the Johns Hopkins Kimmel Cancer Center, the Bloomberg~Kimmel Institute for Cancer Immunotherapy, and the Johns Hopkins Convergence Institute.